Phase 2 Multi-center Trial of ESK981 in Combination With Nivolumab in Patients With Metastatic Renal Cell Carcinoma
Condition: Renal Cell Carcinoma, Metastatic Interventions: Drug: ESK981; Drug: Nivolumab Sponsors: University of Michigan Cancer Center; VA Ann Arbor Healthcare System Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials